Mastozytose – Diagnostisches und therapeutisches Management

Lernziele

Kenntnisse über:

pathogenetische Grundlagen der Mastozytose Symptome der verschiedenen Mastozytoseformen diagnostische Kriterien, Bedeutung der Serumtryptase Prävention von Anaphylaxie, Notfallset therapeutische Hemmung der Mastzelldegranulation und -proliferation

Literatur

• 1 Horny H P, Metcalfe D D, Bennett J et al. Mastocytosis.. In: Jaffe E S, Harris N L, Stein H, Vardiman J W, Hrsg World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues.. Lyon: IARC Press; 2008: 54-63
• 2 Hartmann K, Biedermann T, Brockow K et al. Mastozytose. Leitlinie der Deutschen Gesellschaft für Allergologie und Klinische Immunologie (DGAKI) und der Deutschen Dermatologischen Gesellschaft (DDG).  Allergo J. 2009;  18 196-207
• 3 Valent P, Horny H P, Li C Y et al. Mastocytosis (Mast Cell Disease).. In: Jaffe E S, Harris N L, Stein H, Vardiman J W, Hrsg World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues.. Lyon: IARC Press; 2001: 291-302
• 4 Valent P, Horny H P, Escribano L et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal.  Leuk Res. 2001;  25 603-625
• 5 Valent P, Akin C, Escribano L et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.  Eur J Clin Invest. 2007;  37 435-453
• 6 Hartmann K, Henz B M. Mastocytosis: recent advances in defining the disease.  Br J Dermatol. 2001;  144 682-695
• 7 Hartmann K, Metcalfe D D. Pediatric mastocytosis.  In: Metcalfe DD, Soter NA, Hrsg. Mast Cell Disorders. Hematol Oncol Clin North Am. 2000;  14 625-640
• 8 Bodemer C, Hermine O, Palmérini F et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.  J Invest Dermatol. 2010;  130 804-815
• 9 Hartmann K, Wardelmann E, Ma Y et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.  Gastroenterology. 2005;  129 1042-1046
• 10 Nagata H, Worobec A S, Oh C K et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.  Proc Natl Acad Sci USA. 1995;  92 10 560-10 564
• 11 Orfao A, Garcia-Montero A C, Sanchez L et al. Recent advances in the understanding of mastocytosis: the role of KIT mutations.  Br J Haematol. 2007;  138 12-30
• 12 Daley T, Metcalfe D D, Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin.  Blood. 2001;  98 880-882
• 13 Nedoszytko B, Niedoszytko M, Lange M et al. Interleukin-13 promoter gene polymorphism-1112C/T is associated with the systemic form of mastocytosis.  Allergy. 2009;  64 287-294
• 14 Brockow K, Jofer C, Behrendt H et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.  Allergy. 2008;  63 226-232
• 15 Brockow K, Akin C, Huber M et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology.  J Am Acad Dermatol. 2003;  48 508-516
• 16 Escribano L, Álvarez-Twose I, Sánchez-Munoz L et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.  J Allergy Clin Immunol. 2009;  124 514-521
• 17 Alvarez-Twose I, González de Olano D, Sánchez-Munoz L et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.  J Allergy Clin Immunol. 2010;  125 1269-1278
• 18 Horny H P. Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells.  Am J Clin Pathol. 2009;  132 438-447
• 19 Akin C, Valent P, Metcalfe D D. Mast cell activation syndrome: proposed diagnostic criteria.  J Allergy Clin Immunol. 2010;  126 1099-1104
• 20 Schwartz L B. Diagnostic value of tryptase in anaphylaxis and mastocytosis.  Immunol Allergy Clin North Am. 2006;  26 451-463
• 21 Lange L, Rietschel E, Hunzelmann N et al. Elevated levels of tryptase in children with nummular eczema.  Allergy. 2008;  63 947-949
• 22 Chaar C I, Bell R L, Duffy T P et al. Guidelines for safe surgery in patients with systemic mastocytosis.  Am Surg. 2009;  75 74-80
• 23 Wagner N, Fritze D, Przybilla B et al. Fatal anaphylactic sting reaction in a patient with mastocytosis.  Int Arch Allergy Immunol. 2008;  146 162-163
• 24 Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.  Allergy. 2009;  64 1427-1443
• 25 Carter M C, Robyn J A, Bressler P B et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.  J Allergy Clin Immunol. 2007;  119 1550-1551
• 26 Guhl S, Hartmann K, Tapkenhinrichs S et al. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells.  J Invest Dermatol. 2003;  121 837-844
• 27 Valent P, Sperr W R, Akin C. How I treat patients with advanced systemic mastocytosis.  Blood. 2010;  116 5812-5817
• 28 Gleixner K V, Mayerhofer M, Aichberger K J et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.  Blood. 2006;  107 752-759
• 29 Krauth M T, Mirkina I, Herrmann H et al. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.  Clin Exp Allergy. 2009;  39 1711-1720
• 30 Rueff F, Dugas-Breit S, Przybilla B. Stinging hymenoptera and mastocytosis.  Curr Opin Allergy Clin Immunol. 2009;  9 338-342